Showing 3111-3120 of 4063 results for "".
- Annexon Completes Enrollment in Phase 3 ARCHER II Trial of Vonaprument for GAhttps://modernod.com/news/annexon-completes-enrollment-in-phase-3-archer-ii-trial-of-vonaprument-for-ga/2482901/Annexon announced enrollment has been completed in the phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular degeneration (AMD) with geographic atrophy (GA). The company remains on track to report topline data in the second half of 2026. Accordin
- The Vision Council Comments on Impact of Proposed Tariffs on Optical Industryhttps://modernod.com/news/the-vision-council-comments-on-impact-of-proposed-tariffs-on-optical-industry/2482880/The Vision Council has released a letter summarizing the recent tariffs proposed by the Trump administration and the impact it could have on the optical industry. The White House issued formal notice to several US trading partners outlining tariff
- Opus Genetics' Presbyopia Drop Meets Primary Endpoint in VEGA-3 Phase 3 Trialhttps://modernod.com/news/opus-genetics-announces-vega-3-phase-3-trial-met-primary-endpoint-for-phentolamine-ophthalmic-solution-075-for-the-treatment-of-presbyopia/2482863/Opus Genetics announced positive topline results from VEGA-3, its second pivotal phase 3 trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia. The VEGA-3 trial met its primary endpoint, with a statistically significant 27.2% of participants treated with phe
- PolyActiva Appoints Jerry St. Peter as CEO; Secures Financing to Advance Prezia Technology Platformhttps://modernod.com/news/polyactiva-appoints-jerry-st-peter-as-ceo-secures-financing-to-advance-prezia-technology-platform/2482854/PolyActiva announced two milestones in its next phase of growth: the appointment of biopharmaceutical executive Jerry St. Peter as CEO and board director, and the successful close of a $25M Series C funding round led by an Australian Sovereign Wealth Fund
- Amneal Receives FDA Approval for Prednisolone Acetate Ophthalmic Suspensionhttps://modernod.com/news/amneal-receives-fda-approval-for-prednisolone-acetate-ophthalmic-suspension/2482847/Amneal Pharmaceuticals announced the FDA approval of prednisolone acetate ophthalmic suspension 1% sterile, which references Pred Forte (Allergan, an AbbVie company). Launch of the product is planned for the third quarter of 2025. Prednisolone acetate ophthalmic suspension USP 1% i
- EMA Review Finds Rare Risk of Vision Loss Associated With Semaglutide Medicineshttps://modernod.com/news/ema-review-finds-rare-risk-of-vision-loss-associated-with-semaglutide-medicines/2482842/The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of semaglutide-containing medicines following concerns about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAIO
- EyeCare4Kids Names Maggie Cline as New CEOhttps://modernod.com/news/eyecare4kids-names-maggie-cline-as-new-ceo/2482838/The non-profit EyeCare4Kids announced the promotion of Maggie Cline, MPH, to Chief Executive Officer (CEO). Ms. Cline joined EyeCare4Kids in 2022 and served as Executive Director Utah, where she oversaw the delivery of more than 50,000 vision services annually at school clinics, community centers
- FDA Accepts Tenpoint's New Drug Application for Brimochol PF for the Treatment of Presbyopiahttps://modernod.com/news/fda-accepts-tenpoints-new-drug-application-for-brimochol-pf-for-the-treatment-of-presbyopia/2482832/Tenpoint Therapeutics announced that the FDA has accepted the new drug application (NDA) for Brimochol PF for the treatment of presbyopia. The FDA has set a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026. The FDA noted that it is not planning to hold an advisory co
- CE-Mark Granted to deepeye Medical for AI Tool for Retinal Therapy Planninghttps://modernod.com/news/ce-mark-granted-to-deepeye-medical-for-ai-tool-for-retinal-therapy-planning/2482816/deepeye Medical has received CE Mark for its deepeye TPS¹ (Therapy Planning Support) platform. The Class IIa approval was made under the EU Medical Device Regulation (MDR 2017/745), following certification by the Notified Body
- Hoya Vision Care Presents New Data on Myopia Management Spectacle Lenses at ARVOhttps://modernod.com/news/hoya-vision-care-presents-new-data-on-myopia-management-spectacle-lenses-at-arvo/2482800/Hoya Vision Care announced new clinical evidence from three key clinical studies highlighting the impact of 'Defocus Incorporated Multiple Segments (DIMS)' technology. The results were presented as part of the company’s 2025 scientific program, 'Exploring New Frontiers in Myopia